Welcome to STN International! Enter x:x

LOGINID:ssptacmb1647

```
PASSWORD:
```

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * * *
NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV	21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV	26	MARPAT enhanced with FSORT command
NEWS	4	NOV		CHEMSAFE now available on STN Easy
NEWS	5	NOV		Two new SET commands increase convenience of STN
	-			searching
NEWS	6	DEC		ChemPort single article sales feature unavailable
NEWS	7	DEC	12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC	17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN	06	The retention policy for unread STNmail messages
NEWS		JAN		will change in 2009 for STN-Columbus and STN-Tokyo WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
				Classification Data
NEWS		FEB		Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB	02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB	06	Patent sequence location (PSL) data added to USGENE
NEWS	1.4	FEB	10	COMPENDEX reloaded and enhanced
NEWS		FEB		WTEXTILES reloaded and enhanced
NEWS		FEB		New patent-examiner citations in 300,000 CA/CAplus
NEWS	10	FED	19	patent records provide insights into related prior art
NEWS	17	FEB	19	Increase the precision of your patent queries use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB	23	Several formats for image display and print options discontinued in USPATFULL and USPAT?
NEWS	19	FEB	23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB	23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB	23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB	25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR	06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR	11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR	11	ESBIOBASE reloaded and enhanced
NEWS	EXP	RESS	JUNI	E 27 08 CURRENT WINDOWS VERSION IS V8.3,

ESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008. NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS TPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:39:53 ON 13 MAR 2009

=> file medline embase biosis caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.22 0.22

FILE 'MEDLINE' ENTERED AT 10:40:16 ON 13 MAR 2009

FILE 'EMBASE' ENTERED AT 10:40:16 ON 13 MAR 2009 Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:40:16 ON 13 MAR 2009 Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:40:16 ON 13 MAR 2009 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s DeLeo V?/AU L1 397 DELEO V?/AU

=> s 11 and (FSH and aneuploid and diploid and sperm) L2 0 L1 AND (FSH AND ANEUPLOID AND DIPLOID AND SPERM)

=> s 11 and FSH and sperm L3 0 L1 AND FSH AND SPERM

=> La Marca A?/AU

LA IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s La Marca A?/AU

L4 318 LA MARCA A?/AU

=> s 14 and FSH and sperm

L5 11 L4 AND FSH AND SPERM

=> dup rem 15

PROCESSING COMPLETED FOR L5

5 DUP REM L5 (6 DUPLICATES REMOVED)

=> dis ibib abs 16 1-5

L6 ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:558005 BIOSIS DOCUMENT NUMBER: PREV200600558349

TITLE: Sperm chromosome aneuploidy and gonadotrophin

treatment.

De Leo, V. [Reprint Author]; La Marca, A.; AUTHOR(S): Piomboni, P.; Morgante, G.; Pitaro, M.; Fratoni, A.;

Collodel, G.; Petraglia, F.

CORPORATE SOURCE: Univ Siena, Policlin Scotte, Dept Ob Gyn, I-53100 Siena,

SOURCE:

Italv Human Reproduction (Oxford), (JUN 2006) Vol. 21, No. Suppl.

1, pp. I212.

Meeting Info.: 22nd Annual Meeting of the

European-Society-of-Human-Reproduction-and-Embryology. Prague, CZECH REPUBLIC. June 18 -21, 2006. European Soc

Human Reproduct & Embryol.

CODEN: HUREEE, ISSN: 0268-1161. Conference; (Meeting) DOCUMENT TYPE:

Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE:

Entered STN: 27 Oct 2006 Last Updated on STN: 27 Oct 2006

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:122884 CAPLUS

DOCUMENT NUMBER: 142:170428

TITLE: Use of follicle stimulating hormone for reduction of

spermatozoa chromosomal aberration in males

INVENTOR(S): De Leo, Vincenzo; La Marca, Antonio PATENT ASSIGNEE(S): Laboratoires Serono S.A., Switz.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION: \_\_\_\_\_

	PATENT NO.				KIND DATE			APPLICATION NO.										
					A1 20050210			WO 2004-EP51593										
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
							DE,											
		GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KΡ,	KR,	ΚZ,	LC,	
							LV,											
							PL,											
							TZ,											
	RW:						MW,											
							RU,											
							GR,											
					BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	
			TD,															
	1673						2006			EP 2	004-	7663	06		2	0040	723	
EP	1673																	
	R:						ES,											
							RO,											HR
									JP 2006-521576									
								AT 2004-766306										
								ES 2004-766306										
US 20070037742 A1					2007	0215												
PRIORIT	PRIORITY APPLN. INFO.:								EP 2003-102303 EP 2004-100760									
										WO 2	004-	EP51.	593		W 2	0040	723	

ΔR The present invention relates to the use of a substance having a FSH activity for reducing gamete chromosomal alterations in a male, more specifically in men suffering from spermatozoa aneuploidy. THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 4

ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER: 2005419792 MEDLINE PubMed ID: 16084881 DOCUMENT NUMBER:

TITLE: Comparison of a gonadotropin-releasing hormone (GnRH)

antagonist and GnRH agonist flare-up regimen in poor

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

responders undergoing ovarian stimulation. AUTHOR: Malmusi Stefania; La Marca Antonio; Giulini

Simone; Xella Susanna; Tagliasacchi Daniela; Marsella

Tiziana; Volpe Annibale

CORPORATE SOURCE: Institute of Obstetrics and Gynecology, Policlinico of

Modena, Modena University, Modena, Italy ..

antlamarca@libero.it SOURCE: Fertility and sterility, (2005 Aug) Vol. 84, No. 2, pp.

402-6.

Journal code: 0372772. E-ISSN: 1556-5653.

PUB. COUNTRY: United States

(COMPARATIVE STUDY) DOCUMENT TYPE:

Journal: Article: (JOURNAL ARTICLE)

(RANDOMIZED CONTROLLED TRIAL)

(CLINICAL TRIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200512

Entered STN: 9 Aug 2005 ENTRY DATE: Last Updated on STN: 28 Dec 2005

Entered Medline: 27 Dec 2005

OBJECTIVE: To compare the efficacy of flare-up and GnRH-antagonist AB treatment in poor-responder patients. DESIGN: Randomized prospective study. SETTING: Assisted reproduction center. PATIENT(S): Fifty-five poor-responder patients undergoing intracytoplasmic sperm injection (ICSI). INTERVENTION(S): Thirty patients received GnRH agonist on the 1st day of menstruation, followed by exogenous gonadotropins from the 2nd day. Twenty-five patients received exogenous gonadotropins starting on the second day of menstruation, followed by GnRH antagonist when the leading follicle reached 14 mm in diameter. MAIN OUTCOME MEASURE(S): The total dose of FSH administered during the ovarian stimulation, as well as the number of mature oocytes retrieved, embryo quality, fertilization, implantation, and pregnancy rates were evaluated. RESULT(S): The number of ampules and units of FSH administered were significantly less in the flare-up than in the antagonistic group. The numbers of mature oocytes retrieved and of top-quality embryos transferred were significantly greater in the flare-up than in the GnRH-antagonist group. The fertilization rate (84% vs. 63%) was significantly higher in the flare-up than in the GnRH-antagonist group. The implantation and pregnancy rate were similar in the two groups. CONCLUSION(S): The flare-up protocol appears to be more effective than the GnRH-antagonist protocol in terms of mature occytes retrieved, fertilization rate, and top-quality embryos transferred in poor-responder patients.

L6 ANSWER 4 OF 5 MEDLINE on STN ACCESSION NUMBER: 2005685389 MEDITNE DOCUMENT NUMBER: PubMed ID: 16373249

TITLE: Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome?.

AUTHOR: La Marca Antonio; Pati Mariangela; Giulini

Simone; Levratti Paola; Caretto Simona; Volpe Annibale CORPORATE SOURCE: Department of Obstetrics, Gynecology and Pediatric

University of Modena, Italy.. antlamarca@libero.it

Sciences, Institute of Obstetrics and Gynecology,

Gynecological endocrinology : the official journal of the SOURCE:

International Society of Gynecological Endocrinology, (2005

Nov) Vol. 21, No. 5, pp. 292-4.

Journal code: 8807913. ISSN: 0951-3590. PUB. COUNTRY: England: United Kingdom

LANGUAGE: English

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200604

ENTRY DATE: Entered STN: 24 Dec 2005

Last Updated on STN: 7 Apr 2006 Entered Medline: 6 Apr 2006

BACKGROUND: Raised insulin levels have been shown to contribute to ovarian

ΔR overproduction of androgens. Hyperinsulinemia, usually associated with polycystic ovary syndrome (PCOS), brings about greater ovarian endocrine and morphological responses to ovulation induced by follicle-stimulating hormone (FSH). This indicates that elevated levels of insulin play a role in the endocrine and paracrine control of the ovaries. OBJECTIVE: The aim of the present study was to investigate whether basal insulin levels influence ovarian response to FSH in healthy women (non-PCOS) undergoing assisted reproduction by in vitro fertilization-embryo transfer (IVF-ET). METHODS: The study included 36 consecutive women, 27-45 years old, undergoing IVF-ET for tubal-factor or male-factor infertility. Serum insulin levels were determined on the day of administration of gonadotropin-releasing hormone analog (GnRHa) and on the first day of FSH administration. RESULTS: Mean insulin levels were 6 +/- 3 and 7 +/- 3 microU/ml on the day of GnRHa and FSH administration, respectively. No correlations were found between basal insulin level, days of treatment, total FSH dose, estradiol level and the number of oocytes retrieved. CONCLUSIONS: The results of the present study show that normal levels of insulin do not seem to influence ovarian response to FSH in non-PCOS women. In all patients included in our study, serum insulin levels did not correlate with IVF stimulation data (days of stimulation, total FSH dose)

L6 ANSWER 5 OF 5 MEDLINE on STN DUPLICATE 2

response to FSH administration. ACCESSION NUMBER: 2002629221 MEDIJINE

DOCUMENT NUMBER: PubMed ID: 12351547

TITLE: Insulin-dependent diabetes in men is associated with

hypothalamo-pituitary derangement and with impairment in

semen quality. AUTHOR:

Baccetti Baccio; La Marca Antonio; Piomboni

nor with IVF-ET outcome. Thus the study demonstrates that, in patients who are not insulin-resistant, insulin does not correlate with ovarian

Paola; Capitani Serena; Bruni Emanuele; Petraglia Felice;

De Leo Vincenzo

Department of Pediatrics, Obstetrics and Reproductive CORPORATE SOURCE:

Medicine, University of Siena, Italy.

SOURCE: Human reproduction (Oxford, England), (2002 Oct) Vol. 17,

No. 10, pp. 2673-7.

Journal code: 8701199. ISSN: 0268-1161.

PUB. COUNTRY: England: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200303 AB BACKGROUND: The objective of the study was to investigate the hypothalamo-pituitary-testicular axis and sperm structure at the transmission electron microscope (TEM) level in men affected by insulin-dependent diabetes. METHODS: Twenty-two diabetic men and 24 controls were recruited. GnRH (100 micro q) was administered and FSH- and LH-induced secretion was evaluated. Semen samples were collected and sperm concentration and motility were determined using a Makler chamber. Ejaculated sperm were fixed and observed with a TEM. RESULTS: The response of gonadotrophins to GnRH was significantly lower in diabetics than in control men. Sperm motility was also significantly lower. At the electron microscope level, sperm from diabetics exhibited a higher percentage of immaturityand apoptosis-related defects than sperm from controls. CONCLUSIONS: The reduced response of gonadotrophins to GnRH in diabetic men may indicate a decreased acute releasable pool of pituitary gonadotrophins. The results of TEM examination showed that sperm from men with diabetes presented severe structural defects in comparison with sperm from controls. It is possible that the reproductive impairment recognized in men with diabetes could be the result of interference by the disease on the hypothalamo-pituitary-testicular axis at multiple levels, as indicated by the reduced gonadotrophin response to appropriate stimuli and by the abnormal ultrastructure of ejaculated sperm. The defective spermatogenesis may be the consequence of a direct testicular effect of the disease.

=> FIL STNGUIDE COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL
FULL ESTIMATED COST	31.83	32.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL
CA SUBSCRIBER PRICE	-0.82	-0.82

FILE 'STNGUIDE' ENTERED AT 10:43:05 ON 13 MAR 2009 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Mar 6, 2009 (20090306/UP).

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS
SINCE FILE TOTAL

FULL ESTIMATED COST	ENTRY 0.35	SESSION 32.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	0.00	-0.82

STN INTERNATIONAL LOGOFF AT 10:46:01 ON 13 MAR 2009